The purpose of this experiment is to compared the changes of thyroid function, anti-thyroid peroxidase antibody, anti-thyroglobulin antibody, thyroid magnetic resonance T1-mapping and various metabolic indexes from baseline to the end of treatment (after the thyroid function had been normal for more than three months)
In patients with autoimmune thyroiditis with mild subclinical hypothyroidism, the study period will include a screening period of not more than 30 days, and a 12-week treatment period compared to baseline. At completion of treatment, Thyroid Stimulating Hormone(TSH), free thyroxine (FT4)，free thyroxine (FT3) will be included. The changes of anti-thyroglobulin antibody, anti-thyroglobulin antibody, T1-mapping and metabolic indexes.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Levothyroxine Sodium(50ug/Tablets,dosage form 25ug,once a day) was administered to patients with autoimmune thyroiditis with mild subclinical hypothyroidism,
Beijing Chao-Yang Hospital, Capital Medical University
Beijing, Beijing Municipality, China
RECRUITINGThyroid Stimulating Hormone changes
Thyroid Stimulating Hormone Changes from baseline and 12 weeks during follow-up
Time frame: Thyroid Stimulating Hormone Changes from baseline and 12 weeks during follow-up
free thyroxine changes
free thyroxine changes from baseline and 12 weeks during follow-up
Time frame: free thyroxine changes from baseline and 12 weeks during follow-up
T1-mapping values of Thyroid MRI
T1-mapping values of Thyroid MRI Changes from baseline and 12 weeks during follow-up
Time frame: T1-mapping values of Thyroid MRI Changes from baseline and 12 weeks during follow-up
Free triiodothyronine changes
Free triiodothyronine changes Changes from baseline and 12 weeks during follow-up
Time frame: Free triiodothyronine changes Changes from baseline and 12 weeks during follow-up
anti-thyroid peroxidase antibody changes
anti-thyroid peroxidase antibody changes from baseline and 12 weeks during follow-up
Time frame: anti-thyroid peroxidase antibody changes from baseline and 12 weeks during follow-up
anti-thyroglobulin antibody changes
anti-thyroglobulin antibody changes from baseline and 12 weeks during follow-up
Time frame: anti-thyroglobulin antibody changes from baseline and 12 weeks during follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.